Pembrolizumab,eftilagimod
Merck,novartis
['head and neck', 'immutep']
press release: reports final #positivedata in second-line head and neck squamous cell #carcinoma at #asco2023 annual meeting. to read more, visit: 
IB Communications is an international communications agency specialising in healthcare & life sciences with specific expertise in the cell & gene therapy sector